•  
  •  
 

Rehabilitation Practice and Science

Translated Title

肉毒桿菌毒素治療腦性麻痺兒童痙攣之臨床成效

Abstract

Botulinum toxin type A (BTA) has treated spasticity in cerebral palsy (CP) in recent years. This study investigated both the clinical effects and gait improvements of BTA on spasticity management in children with CP.Twenty-nine children with spastic CP (2-10 years old) were recruited into this study. All subjects received complete clinical assessments, video recording and functional assessments before and 1-3 months after BTA treatment. A questionnaire was employed for the evaluation of parents’ subjective satisfaction. Clinical assessments included muscle tone and joint range of motion (ROM) of bilateral lower limbs. ROMs, including dynamic (R1) and static (R2), were measured by Modified Tardieu Scale. Functional assessments comprised Gross Motor Function Measure (GMFM) and Minear’s classification. Gait on videotape was analyzed by observational gait scale (OGS) Three months after BTA injection, the muscle tone decreased significantly in all muscles. R1 improved in all muscle groups (P＜0.01); however, R2 slightly improved in hip adductors and hamstrings (P＜0.05). Meanwhile, GMFM and Minear’s scores also had significant improvement (P＜0.05). The OGS scores improved significantly in most gait parameters (P＜0.05) except knee position and hindfoot at midstance. Moreover, most parents considered children’s ability of daily living improved. All parents believed children’s walking ability improved as well. The results reveaed that BTA treatment could improve ROM, gross motor, functional ability and gait by reducing the muscle tone.

Language

Traditional Chinese

First Page

171

Last Page

180

Download

Share

COinS